[10 Things Cardiologists Need to Know About Cardiac Amyloidosis].

Authors

Simon F Stämpfli

Published in

Praxis. Volume 115. Issue 8. Pages 229-232.

Abstract

Transthyretin amyloid cardiomyopathy (ATTR-CM) is an increasingly recognized cause of heart failure, arrhythmias, and conduction disease. After exclusion of light-chain amyloidosis, diagnosis can often be established non-invasively by bone scintigraphy with SPECT. Disease-modifying therapies are now available in Switzerland and are most effective when initiated early. Management should also address heart failure, atrial fibrillation, thromboembolic risk, conduction disorders, and concomitant aortic stenosis. Early recognition and multidisciplinary treatment are therefore essential to improve outcomes.

PMID:
42708203
Bibliographic data and abstract were imported from PubMed on 08 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.